Phase 2 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of various aleniglipron (GSBR-1290) dose regimens compared with placebo in participants living with obesity or overweight with ≥ 1 weight-related comorbidity, in addition to diet and exercise, over a 44-week period.
Phase 2 trials begin testing efficacy in a larger patient group (100–300). This is often where biotech binary events occur — positive Phase 2 data can significantly advance a company's pipeline narrative, while failures can be terminal for a program.
This trial has completed. Results may be available via ClinicalTrials.gov or peer-reviewed publications.
Structure Therapeutics (GPCR) is the sponsoring company for this trial. BiotechSign currently grades this company C (50/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.